The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 08, 2022

Filed:

Sep. 20, 2017
Applicants:

Memorial Sloan-kettering Cancer Center, New York, NY (US);

Eureka Therapeutics, Inc., Emeryville, CA (US);

Inventors:

David A. Scheinberg, New York, NY (US);

Tao Dao, New York, NY (US);

Cheng Liu, Oakland, CA (US);

Assignees:

MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY (US);

EUREKA THERAPEUTICS, INC., Emeryville, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/40 (2006.01); C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/40 (2013.01); A61K 39/0011 (2013.01); A61K 47/6871 (2017.08); C07K 16/2809 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01); C07K 2319/70 (2013.01);
Abstract

Antigen binding proteins specific for an HLA-A2 restricted Ras peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab')2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, and bispecific antibodies incorporating the specificity of the antigen binding region for each peptide are also contemplated by the disclosure. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the disclosure. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.


Find Patent Forward Citations

Loading…